Eisai Co. Ltd., has firmed up a licensing deal with Mylan NV for a second brand of Halaven (eribulin mesylate), as the Japanese company seeks to expand availability and access to the anticancer on the Indian market amid the recent arrival of a cut-price rival.
The licensing agreement will see Mylan India promote and distribute the second brand, Teceris, in the country, with eribulin being...







